MRPL20-DT

Across TCGA pan-cancer cohorts, MRPL20-DT RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of MRPL20-DT’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MRPL20-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MRPL20-DT is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

KIRC, COAD, and HNSC are the cancer types where MRPL20-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MRPL20-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.634	<.001	12	view →
COAD	Female	II,III,IV	+1.252	<.001	11	view →
HNSC	All	IV	+0.687	<.001	11	view →
LUAD	Female	All	+1.129	<.001	9	view →
BLCA	All	III,IV	+1.007	<.001	9	view →
STAD	Male	II,III,IV	+1.247	<.001	8	view →
LUSC	Female	All	+1.459	<.001	7	view →
READ	Female	All	+1.266	<.001	7	view →
KIRP	All	III,IV	+0.875	.002	7	view →
LIHC	Male	All	+0.734	<.001	7	view →
BRCA	Female	All	+0.599	<.001	6	view →
THCA	Female	All	+0.559	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

MRPL20-DT–KIRC

Open the KIRC breakdown →